Bridgeway Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Bridgeway Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-95,143	Closed	-$660K	–	1305
2024 Q3	$660K	Hold	95,143	–	–	0.01%	791
2024 Q2	$466K	Hold	95,143	–	–	0.01%	874
2024 Q1	$552K	Hold	95,143	–	–	0.01%	897
2023 Q4	$623K	Hold	95,143	–	–	0.01%	888
2023 Q3	$459K	Hold	95,143	–	–	0.01%	904
2023 Q2	$485K	Hold	95,143	–	–	0.01%	912
2023 Q1	$523K	Buy	95,143 +5,700	+6%	+$30.2K	0.01%	875
2022 Q4	$411K	Buy	89,443 +20,500	+30%	+$104K	0.01%	930
2022 Q3	$430K	Hold	68,943	–	–	0.01%	927
2022 Q2	$307K	Buy	+68,943	New	+$314K	0.01%	991
2019 Q4	–	Sell	-8,138	Closed	-$90K	–	1395
2019 Q3	$90K	Hold	8,138	–	–	﹤0.01%	1251
2019 Q2	$228K	Hold	8,138	–	–	﹤0.01%	1157
2019 Q1	$217K	Buy	8,138 +4,700	+137%	+$173K	﹤0.01%	1212
2018 Q4	$98K	Hold	3,438	–	–	﹤0.01%	1307
2018 Q3	$264K	Buy	+3,438	New	+$269K	﹤0.01%	1277

Other funds holding ZVRA

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bridgeway Capital Management's ZVRA Position: Q4 2024 in Review

Bridgeway Capital Management sold out of Zevra Therapeutics (ZVRA) in Q4 2024, closing a stake of 95,143 shares — an estimated $660K sold.

Bridgeway Capital Management first reported a position in ZVRA in Q3 2018 and held it in 15 quarters. The position peaked at $660K in Q3 2024. 109 funds tracked by Wall St. Rank hold ZVRA as of Q4 2024.

Bridgeway Capital Management reported no remaining Zevra Therapeutics position as of Q4 2024 after selling out during the quarter.
Bridgeway Capital Management sold 95,143 Zevra Therapeutics shares in Q4 2024, an estimated $660K.
Bridgeway Capital Management first reported a position in Zevra Therapeutics in Q3 2018 and held it in 15 quarters.
Bridgeway Capital Management's Zevra Therapeutics position peaked at $660K in Q3 2024.
109 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2024.

Based on Bridgeway Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.